Abstract
Changes induced by i.v. and subcutaneous teprotide in plasma renin, angiotensin I, angiotensin II, aldosterone and bradykinin were studied in a renal transplant patient with severe high renin hypertension, before and after trinephrectomy. The immediate reduction in BP produced by teprotide was not solely attributable to the inhibition of conversion of angiotensin I to angiotensin II, because there was also a transient increase in serum bradykinin; however, the prolonged antihypertensive effect of teprotide appeared independent of bradykinin. After trinephrectomy, teprotide lowered systolic BP but had no significant effect on diastolic BP or plasma bradykinin. beta-Blockade prevented the secondary increase in plasma renin which followed teprotide, thereby potentiating its anti-hypertensive effect.
Full text
PDF





Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Erdös E. G. Angiotensin I converting enzyme. Circ Res. 1975 Feb;36(2):247–255. doi: 10.1161/01.res.36.2.247. [DOI] [PubMed] [Google Scholar]
- Fraser R., Guest S., Young J. A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man. Clin Sci Mol Med. 1973 Sep;45(3):411–415. doi: 10.1042/cs0450411. [DOI] [PubMed] [Google Scholar]
- Johnston C. I., Millar J. A., McGrath B. P., Matthews P. G. Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension. Lancet. 1979 Sep 8;2(8141):493–496. doi: 10.1016/s0140-6736(79)91552-6. [DOI] [PubMed] [Google Scholar]
- Leslie B. R., Case D. B., Sullivan J. F., Vaughan E. D., Jr Absence of blood-pressure lowering effect of captopril in anephric patients. Br Med J. 1980 Apr 19;280(6221):1067–1068. doi: 10.1136/bmj.280.6221.1067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Man in 't Veld A. J., Schicht I. M., Derkx F. H., de Bruyn J. H., Schalekamp M. A. Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. Br Med J. 1980 Feb 2;280(6210):288–290. doi: 10.1136/bmj.280.6210.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miller E. D., Jr, Samuels A. I., Haber E., Barger A. C. Inhibition of angiotensin conversion and prevention of renal hypertension. Am J Physiol. 1975 Feb;228(2):448–453. doi: 10.1152/ajplegacy.1975.228.2.448. [DOI] [PubMed] [Google Scholar]
- Nasjletti A., Colina-Chourio J., McGiff J. C. Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition. Circ Res. 1975 Jul;37(1):59–65. doi: 10.1161/01.res.37.1.59. [DOI] [PubMed] [Google Scholar]
- Rosen M. R., Hoffman B. F. The cost of scientific communication: the scientist as ad-man. Circ Res. 1977 Jan;40(1):1–2. doi: 10.1161/01.res.40.1.1. [DOI] [PubMed] [Google Scholar]
- Sancho J., Re R., Burton J., Barger A. C., Haber E. The role of the renin-angiotensin-aldosterone system in cardiovascular homeostasis in normal human subjects. Circulation. 1976 Mar;53(3):400–405. doi: 10.1161/01.cir.53.3.400. [DOI] [PubMed] [Google Scholar]
- Swartz S. L., Williams G. H., Hollenberg N. K., Moore T. J., Dluhy R. G. Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation. Hypertension. 1979 Mar-Apr;1(2):106–111. doi: 10.1161/01.hyp.1.2.106. [DOI] [PubMed] [Google Scholar]
- Talamo R. C., Haber E., Austen K. F. A radioimmunoassay for bradykinin in plasma and synovial fluid. J Lab Clin Med. 1969 Nov;74(5):816–827. [PubMed] [Google Scholar]
- Thurston H., Swales J. D. Converting enzyme inhibitor and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor. Circ Res. 1978 May;42(5):588–592. doi: 10.1161/01.res.42.5.588. [DOI] [PubMed] [Google Scholar]
- Vandenburg M. J., Sharman V. L., Marsh F. P., Rucinska E. J. Prolonged treatment of high-renin hypertension with a converting enzyme inhibitor. Br Med J. 1978 Sep 23;2(6141):866–866. doi: 10.1136/bmj.2.6141.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vinci J. M., Horwitz D., Zusman R. M., Pisano J. J., Catt K. J., Keiser H. R. The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man. Hypertension. 1979 Jul-Aug;1(4):416–426. doi: 10.1161/01.hyp.1.4.416. [DOI] [PubMed] [Google Scholar]
- Williams G. H., Hollenberg N. K. Accentuated vascular and endocrine response to SQ 20881 in hypertension. N Engl J Med. 1977 Jul 28;297(4):184–188. doi: 10.1056/NEJM197707282970404. [DOI] [PubMed] [Google Scholar]
- Yang H. Y., Erdös E. G., Levin Y. Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther. 1971 Apr;177(1):291–300. [PubMed] [Google Scholar]
